Pandemic influenza vaccine: exploiting the conserved HA cleavage site

大流行性流感疫苗：利用保守的 HA 裂解位点

• 批准号: nhmrc : 399298
• 负责人: Dr David Boyle
• 金额: $ 16.22万
• 依托单位: The University of Adelaide
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Strategic Awards
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-01-01 至 2006-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/pandemic-influenza-vaccine-cleavage-site/78172
• 关键词: Pandemic; influenza; vaccine; exploiting; conserved

Influenza virus needs to cleave its surface spike protein, hemagglutinin or HA, to become mature and infectious. This project is aimed at producing a vaccine that will block the cleavage thus rendering the virus non-infectious. To achieve this, we will use synthetic fragments (called peptides) of the viral HA spike protein mimicking its cleavage site to immunize mice. This will produce specific antibodies that will bind to the cleavage site while the virus is inside the infected cell, thus preventing the viral spike protein from being cleaved and remain immature. This idea is particularly suited to fight the bird flu, as all pathogenic bird influenza viruses cleave HA spike proteins within the infected cell.

流感病毒需要裂解其表面刺突蛋白，血凝素或HA，以变得成熟和具有感染性。该项目的目的是生产一种疫苗，将阻止切割，从而使病毒无传染性。为了实现这一点，我们将使用模拟其切割位点的病毒HA刺突蛋白的合成片段（称为肽）来免疫小鼠。这将产生特异性抗体，当病毒在感染细胞内时，抗体将结合到切割位点，从而防止病毒刺突蛋白被切割并保持不成熟。这个想法特别适合于对抗禽流感，因为所有致病性禽流感病毒都会在感染细胞内切割HA刺突蛋白。